Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04757116Not ApplicableRecruiting

Post-Market Study to Assess iTind Safety in Comparison to UroLift

Role: collaborator

NCT05869838Completed

A Clinical Study on Endoscopic and Histopathological Outcomes of Screening and Surveillance Colonoscopies

Role: lead

NCT07253727Not Yet Recruiting

The LUCENT Study - LUng Lesion Assessment Via BF-UCP190F for Central and Extended Nodal Targeting

Role: lead

NCT05129449Completed

A Clinical Study With the Medical Device PowerSpiral for Endoscopic Retrograde Cholangio-Pancreatography (ERCP)

Role: lead

NCT05943288Completed

Safety and Efficacy of the Olympus CADe System in Real-time Colonoscopy

Role: lead

NCT03955081Completed

A Clinical Study With the Medical Device PowerSpiral for Deep Enteroscopy

Role: lead

All 6 trials loaded